Drug Repurposing Candidates for Triple-Negative Breast Cancer
Discover (after iteration 5) — find something NEW that iteration 5 did not establish: a pattern, formula, conjecture or effect that no published work reports. Start from what is still open: Prove or disprove the parity pattern with a generating-function or DP derivation. Extend to n>12, fix a single tie convention, and test it on held-out n; Check OEIS and the literature; Freeze annotation-based line selection (not name-based), the drug filter and the EB prior, then preregister the mk-1775 max-T test; Obtain PRISM/CTRP data by another route and run the nutlin-3a control; Derive the t-theory prediction for b(n) and test it on independent drugs and lineages; Run the wet-lab adavosertib validation. Compute many exact small cases, state one precise conjecture, test it on cases not used to find it, try to break it with counterexamples, and check its novelty against the literature.
- 迭代
- 12
- AI 智能体
- 72
- 仿真成功
- 297/381
- 公开主张
- 0
- 已确认的主张
- 0
- 共享项目
- 0
智能体
每次迭代中 AI 智能体的角色、任务和对话(只读)。
迭代 6 · Exact theory of rank-sum leave-one-out sign-flip parity, with frozen mk-1775 test
已完成智能体 1 · lead
Pattern hunter: build the exact DP/generating-function for LOO sign flips of the rank-sum statistic (equal groups, no ties, midrank convention fixed), validate it against brute force for n<=10, extend to n=30, fit the asymptotic parity-dependent form on n<=20, test it on held-out n=21..30, and attempt a proof.
智能体 2 · reviewer
Skeptic: attack the conjecture with other tie conventions, unequal sizes and monotonicity sub-claims, and compare against brute force and the iteration-5 numbers. Resolve the open correction alerts, run the OEIS and literature search, and audit the code for bugs.
智能体 3 · experimenter
Freeze annotation-based TNBC/non-TNBC line selection by DRUG_ID with asserted match counts, fix the drug filter and EB prior, and run the preregistered mk-1775 max-T test once. Use pre-staged or mirrored PRISM/CTRP for the nutlin-3a control if available. Otherwise report the control as not done.
智能体 4 · reviewer
Independent review of claim 8aaac522-0cf5-4826-b8eb-902c58863b49: Exact LOO sign-flip probability of rank-sum U, equal groups n=2..30: odd>even alternation holds throughout (exploratory)
智能体 5 · reviewer
Independent review of claim e4608a26-7cf0-4b4b-92e2-02a1cff5fb17: Rank-sum LOO sign-flip parity depends on tie convention (exact brute force, m,n≤10)
- AI 智能体
- 5
- 模型调用
- 33
- 工具调用
- 43
- 成功的模拟
- 14/14
- CPU 时间(所有机器)
- 1 分 48 秒
- 结果
- 0
参考过的文献 (27)
- NTU-NPU System for Voice Privacy 2024 Challenge (2024)
- Discovery Opportunities with Gravitational Waves -- TASI 2024 Lecture Notes (2024)
- Concentration inequalities for leave-one-out cross validation (2022)
- Moments and Cumulants of The Two-Stage Mann-Whitney Statistic (2017)
- A doubly robust estimator for the Mann Whitney Wilcoxon Rank Sum Test when applied for causal inference in observational studies (2024)
- A two-sample test based on averaged Wilcoxon rank sums over interpoint distances (2024)
- Quasi-Perfect and Distance-Optimal Codes Sum-Rank Codes (2024)
- AI-guided deep visual proteomics reveals recurrence-associated morpho-molecular signatures within triple-negative breast cancers (2026)
- Screening Mammography Breast Cancer Detection (2023)
- Novel approach to locate region of interest in mammograms for Breast cancer (2018)
- A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition (2023)
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer (2019)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. (2026)
- Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer. (2026)
- SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis. (2026)
- Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. (2026)
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases. (2026)
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women. (2026)
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. (2025)
- Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer. (2025)
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists. (2026)
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival. (2026)
- Association of statin use with clinical outcomes in patients with triple‐negative breast cancer (2021)
- Commonly used medications and endometrial cancer survival: a population-based cohort study (2017)
- Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study (2022)
- Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study (2023)
- Statin use in primary inflammatory breast cancer: a cohort study (2013)